SUMITOMO CHEMICAL COMPANY,LIMITED [4005.T]
TOKYO, May 13 (Pulse News Wire) – Sumitomo Chemical Company,limited (4005.T) disclosed today that its subsidiary, Sumitomo Pharma Co., Ltd., reported higher revenue and profits for the fiscal year ended March 31, 2026, compared to the previous fiscal year. For the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026), Sumitomo Pharma recorded revenues of 249,530 million yen, operating profit of 19,359 million yen, ordinary profit of 62,940 million yen, and net profit of 114,981 million yen.
In contrast, for the fiscal year ending March 31, 2025 (April 1, 2024 to March 31, 2025), the corresponding figures were 136,412 million yen, 11,603 million yen, 12,028 million yen, and 106,187 million yen respectively. The increase in sales was attributed to the acquisition of assets, including patents related to three key products in the United States, from its wholly-owned subsidiary, Sumitomo Pharma Switzerland GmbH (SMPS). As a result, Sumitomo Pharma's product sales increased significantly.
Additionally, the rise in operating income, coupled with dividend income received from SMPS, contributed to higher ordinary profits. Special gains from the partial divestment of Asian operations also boosted net profits. Despite these changes, Sumitomo Chemical stated that the impact on its consolidated earnings forecast remains minor.
🟢 Confidence: High AI-translated content.